Nasus Pharma Ltd

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company that develops powder-based intranasal medications for acute and emergency medical situations. The company utilizes proprietary technology to deliver uniform spherical powder formulations into the nasal cavity for rapid drug absorption. Its primary product candidate is NS002, an intranasal epinephrine powder spray designed to treat severe allergic reactions. It also develops NS001, an intranasal naloxone candidate for opioid overdose, alongside preclinical programs exploring intranasal treatments for seizures, organophosphate poisoning, and vomiting. Because its product candidates remain in clinical development without regulatory approval, the company currently has no commercial customers, targeting patients who require immediate emergency care.

The company is incorporated and headquartered in Tel Aviv, Israel. It operates as a development-stage enterprise without commercial manufacturing facilities, relying on external contractors for drug supply, clinical operations, and laboratory materials. Its research footprint includes clinical trial operations in Canada, where it evaluates its investigational therapies in adult patient cohorts.

Summary of the business section of Nasus Pharma's latest annual report, written by StockData.